Claims
- 1. A method of therapeutically downmodulating an autoimmune response in a subject comprising administering an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated.
- 2. The method of claim 1, wherein the antigen binding portion is an scFv molecule or an Fab fragment.
- 3. The method of claim 1, wherein the antigen binding portion is humanized.
- 4. The method of claim 1, wherein the antigen binding portion is fully human.
- 5. A method of therapeutically downmodulating an autoimmune response in a subject comprising administering a small molecule that specifically blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated.
- 6. The method of claim 1 or 5, wherein the autoimmune response is mediated by CD4+ T cells.
- 7. The method of claim 1 or 5, wherein the autoimmune response is mediated by CD8+ T cells.
- 8. The method of claim 1 or 5, wherein the autoimmune response is type I diabetes.
- 9. A method of therapeutically downmodulating an ongoing autoimmune response in a subject comprising administering an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an ongoing autoimmune response in the subject is downmodulated.
- 10. The method of claim 9, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
- 11. The method of claim 9, wherein the antigen-binding portion is humanized.
- 12. The method of claim 9, wherein the antigen-binding portion is fully human.
- 13. A method of therapeutically downmodulating an ongoing autoimmune response in a subject comprising administering a small molecule that specifically blocks signaling via CD28 to the subject such that an ongoing autoimmune response in the subject is downmodulated.
- 14. The method of claim 9 or 13, wherein the autoimmune response is mediated by CD4+ T cells.
- 15. The method of claim 9 or 13, wherein the autoimmune response is mediated by CD8+ T cells.
- 16. The method of claim 9 or 13, wherein the autoimmune response is type I diabetes.
- 17. A method of prophylactically downmodulating an autoimmune response in a subject comprising administering an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated or delayed in its onset.
- 18. The method of claim 17, wherein the antigen binding portion is a scFv molecule or an Fab fragment.
- 19. The method of claim 17, wherein the antigen-binding portion is humanized.
- 20. The method of claim 17, wherein the antigen-binding portion is fully human.
- 21. A method of prophylactically downmodulating an autoimmune response in a subject comprising administering a small molecule that specifically blocks signaling via CD28 to the subject such that an autoimmune response in the subject is downmodulated or delayed in its onset.
- 22. The method of claim 17 or 21, wherein the autoimmune response is mediated by CD4+ T cells.
- 23. The method of claim 17 or 21, wherein the autoimmune response is mediated by CD8+ T cells.
- 24. The method of claim 17 or 21, wherein the autoimmune response is type I diabetes.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Ser. No. 60/269,756, filed on Feb. 16, 2001. The entire contents of that application are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60269756 |
Feb 2001 |
US |